IL-1β is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease

Journal of Immunology

Volumn 186, Issue 3, 2011, Pages 1870-1879

  Pathak, Shresh ^a   Goldofsky, Elliot ^b   Vivas, Esther X ^b   Bonagura, Vincent R ^a   Vambutas, Andrea ^a,b  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; GELATINASE B; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 1BETA; PREDNISONE;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE INNER EAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DRUG DOSE REDUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INNER EAR DISEASE; MALE; MONOCYTE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AUTOIMMUNE DISEASES; CELLS, CULTURED; COCHLEAR IMPLANTATION; DEXAMETHASONE; FEMALE; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HEARING LOSS, SENSORINEURAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1BETA; MALE; MATRIX METALLOPROTEINASE 9; PREDNISONE; PROSPECTIVE STUDIES;

EID: 79251570253     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002275     Document Type: Article

References (54)

1. Ruckenstein, M. J. 2004. Autoimmune inner ear disease. Curr. Opin. Otolaryngol. Head Neck Surg. 12: 426-430.
2. Berrocal, J. R., and R. Ramírez-Camacho. 2002. Sudden sensorineural hearing loss: supporting the immunologic theory. Ann. Otol. Rhinol. Laryngol. 111: 989-997.
3. Agrup, C., and L. M. Luxon. 2006. Immune-mediated inner-ear disorders in neuro-otology. Curr. Opin. Neurol. 19: 26-32.
4. Ryan, A. F., J. P. Harris, and E. M. Keithley. 2002. Immune-mediated hearing loss: basic mechanisms and options for therapy. Acta Otolaryngol. (Suppl. 548): 38-43.
5. Niparko, J. K., N. Y. Wang, S. D. Rauch, G. B. Russell, M. A. Espeland, J. J. Pierce, S. Bowditch, A. Masuda, A. J. Gulya, B. J. Gantz, et al; AIED Study Group. 2005. Serial audiometry in a clinical trial of AIED treatment. Otol. Neurotol. 26: 908-917.
6. McCabe, B. F. 1979. Autoimmune sensorineural hearing loss. Ann. Otol. Rhinol. Laryngol. 88: 585-589.
7. Harris, J. P., M. H. Weisman, J. M. Derebery, M. A. Espeland, B. J. Gantz, A. J. Gulya, P. E. Hammerschlag, M. Hannley, G. B. Hughes, R. Moscicki, et al. 2003. Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA 290: 1875-1883.
8. Broughton, S. S., W. E. Meyerhoff, and S. B. Cohen. 2004. Immune-mediated inner ear disease: 10-year experience. Semin. Arthritis Rheum. 34: 544-548.
9. Sims, J. E., and D. E. Smith. 2010. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10: 89-102.
10. Sutton, C., C. Brereton, B. Keogh, K. H. Mills, and E. C. Lavelle. 2006. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203: 1685-1691.
11. Lee, W. W., S. W. Kang, J. Choi, S. H. Lee, K. Shah, E. E. Eynon, R. A. Flavell, and I. Kang. 2010. Regulating human Th17 cells via differential expression of IL-1 receptor. Blood 115: 530-540.
12. Hashimoto, S., P. Billings, J. P. Harris, G. S. Firestein, and E. M. Keithley. 2005. Innate immunity contributes to cochlear adaptive immune responses. Audiol. Neurootol. 10: 35-43.
13. Henderson, C., and R. Goldbach-Mansky. 2010. Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals. Clin. Immunol. 135: 210-222.
14. Hawkins, P. N., H. J. Lachmann, E. Aganna, and M. F. McDermott. 2004. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 50: 607-612.
15. Mirault, T., D. Launay, L. Cuisset, E. Hachulla, M. Lambert, V. Queyrel, T. Quemeneur, S. Morell-Dubois, and P. Y. Hatron. 2006. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum. 54: 1697-1700.
16. Mantovani, A., R. Bonecchi, F. O. Martinez, E. Galliera, P. Perrier, P. Allavena, and M. Locati. 2003. Tuning of innate immunity and polarized responses by decoy receptors. Int. Arch. Allergy Immunol. 132: 109-115.
17. Mantovani, A., M. Muzio, P. Ghezzi, C. Colotta, and M. Introna. 1998. Regulation of inhibitory pathways of the interleukin-1 system. Ann. N. Y. Acad. Sci. 840: 338-351.
18. Amano, Y., S. W. Lee, and A. C. Allison. 1993. Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6: mediation by decreased mRNA stability. Mol. Pharmacol. 43: 176-182.
19. Lorenz, R. R., C. A. Solares, P. Williams, J. Sikora, C. M. Pelfrey, G. B. Hughes, and V. K. Tuohy. 2002. Interferon-gamma production to inner ear antigens by T cells from patients with autoimmune sensorineural hearing loss. J. Neuroimmunol. 130: 173-178.
20. Dickensheets, H. L., and R. P. Donnelly. 1997. IFN-gamma and IL-10 inhibit induction of IL-1 receptor type I and type II gene expression by IL-4 and IL-13 in human monocytes. J. Immunol. 159: 6226-6233.
21. Docagne, F., S. J. Campbell, A. F. Bristow, S. Poole, S. Vigues, C. Guaza, V. H. Perry, and D. C. Anthony. 2005. Differential regulation of type I and type II interleukin-1 receptors in focal brain inflammation. Eur. J. Neurosci. 21: 1205-1214.
22. Vambutas, A., J. DeVoti, E. Goldofsky, M. Gordon, M. Lesser, and V. Bonagura. 2009. Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED. PLoS ONE 4: e5293.
23. Orlando, S., M. Sironi, G. Bianchi, A. H. Drummond, D. Boraschi, D. Yabes, and A. Mantovani. 1997. Role of metalloproteases in the release of the IL-1 type II decoy receptor. J. Biol. Chem. 272: 31764-31769.
24. Neumann, D., C. Kollewe, M. U. Martin, and D. Boraschi. 2000. The membrane form of the type II IL-1 receptor accounts for inhibitory function. J. Immunol. 165: 3350-3357.
25. Yokoo, T., and M. Kitamura. 1996. Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. Am. J. Physiol. 270: F123-F130.
26. Cundall, M., Y. Sun, C. Miranda, J. B. Trudeau, S. Barnes, and S. E. Wenzel. 2003. Neutrophil-derived matrix metalloproteinase-9 is increased in severe asthma and poorly inhibited by glucocorticoids. J. Allergy Clin. Immunol. 112: 1064-1071.
27. Benesová, Y., A. Vasku, H. Novotná, J. Litzman, P. Stourac, M. Beránek, Z. Kadanka, and J. Bednarík. 2009. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult. Scler. 15: 316-322.
28. Hu, W., J. Metselaar, L. H. Ben, P. D. Cravens, M. P. Singh, E. M. Frohman, T. N. Eagar, M. K. Racke, B. C. Kieseier, and O. Stüve. 2009. PEG minocyclineliposomes ameliorate CNS autoimmune disease. PLoS ONE 4: e4151.
29. Yamaguchi, M., V. Jadhav, A. Obenaus, A. Colohan, and J. H. Zhang. 2007. Matrix metalloproteinase inhibition attenuates brain edema in an in vivo model of surgically-induced brain injury. Neurosurgery 61: 1067-1075, discussion 1075-1076.
30. Corbacella, E., I. Lanzoni, D. Ding, M. Previati, and R. Salvi. 2004. Minocycline attenuates gentamicin induced hair cell loss in neonatal cochlear cultures. Hear. Res. 197: 11-18.
31. Brown, E. A., H. A. Dare, C. B. Marsh, and M. D. Wewers. 1996. The combination of endotoxin and dexamethasone induces type II interleukin 1 receptor (IL-1r II) in monocytes: a comparison to interleukin 1 beta (IL-1 beta) and interleukin 1 receptor antagonist (IL-1ra). Cytokine 8: 828-836.
32. Liu, C., R. P. Hart, X. J. Liu, W. Clevenger, R. A. Maki, and E. B. De Souza. 1996. Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA. J. Biol. Chem. 271: 20965-20972.
33. Moscicki, R. A., J. E. San Martin, C. H. Quintero, S. D. Rauch, J. B. J. Nadol, Jr., and K. J. Bloch. 1994. Serum antibody to inner ear proteins in patients with progressive hearing loss: correlation with disease activity and response to corticosteroid treatment. JAMA 272: 611-616.
34. Distler, J. H., A. Jüngel, L. C. Huber, C. A. Seemayer, C. F. Reich, III, R. E. Gay, B. A. Michel, A. Fontana, S. Gay, D. S. Pisetsky, and O. Distler. 2005. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc. Natl. Acad. Sci. USA 102: 2892-2897.
35. Lee, S. W., A. P. Tsou, H. Chan, J. Thomas, K. Petrie, E. M. Eugui, and A. C. Allison. 1988. Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA. Proc. Natl. Acad. Sci. USA 85: 1204-1208.
36. Granowitz, E. V., E. Vannier, D. D. Poutsiaka, and C. A. Dinarello. 1992. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis. II. IL-1 receptor antagonist inhibits lipopolysaccharide-induced cytokine synthesis by human monocytes. Blood 79: 2364-2369.
37. Granowitz, E. V., B. D. Clark, E. Vannier, M. V. Callahan, and C. A. Dinarello. 1992. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis. I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood 79: 2356-2363.
38. Hirose, K., C. M. Discolo, J. R. Keasler, and R. Ransohoff. 2005. Mononuclear phagocytes migrate into the murine cochlea after acoustic trauma. J. Comp. Neurol. 489: 180-194.
39. Fujioka, M., S. Kanzaki, H. J. Okano, M. Masuda, K. Ogawa, and H. Okano. 2006. Proinflammatory cytokines expression in noise-induced damaged cochlea. J. Neurosci. Res. 83: 575-583.
40. Tabuchi, K., H. Murashita, S. Sakai, T. Hoshino, I. Uemaetomari, and A. Hara. 2006. Therapeutic time window of methylprednisolone in acoustic injury. Otol. Neurotol. 27: 1176-1179.
41. Solares, C. A., A. E. Edling, J. M. Johnson, M. J. Baek, K. Hirose, G. B. Hughes, and V. K. Tuohy. 2004. Murine autoimmune hearing loss mediated by CD4+ T cells specific for inner ear peptides. J. Clin. Invest. 113: 1210-1217.
42. Baek, M. J., H. M. Park, J. M. Johnson, C. Z. Altuntas, D. Jane-Wit, R. Jaini, C. A. Solares, D. M. Thomas, E. J. Ball, N. G. Robertson, et al. 2006. Increased frequencies of cochlin-specific T cells in patients with autoimmune sensorineural hearing loss. J. Immunol. 177: 4203-4210.
43. Kern, J. A., R. J. Lamb, J. C. Reed, R. P. Daniele, and P. C. Nowell. 1988. Dexamethasone inhibition of interleukin 1 beta production by human monocytes: posttranscriptional mechanisms. J. Clin. Invest. 81: 237-244.
44. Goleva, E., P. J. Hauk, J. Boguniewicz, R. J. Martin, and D. Y. Leung. 2007. Airway remodeling and lack of bronchodilator response in steroid-resistant asthma. J. Allergy Clin. Immunol. 120: 1065-1072.
45. Goleva, E., P. J. Hauk, C. F. Hall, A. H. Liu, D. W. Riches, R. J. Martin, and D. Y. Leung. 2008. Corticosteroid-resistant asthma is associated with classical antimicrobial activation of airway macrophages. J. Allergy Clin. Immunol. 122: 550-559, e3.
46. Markova, S., T. Nakamura, H. Makimoto, T. Ichijima, M. Yamamori, A. Kuwahara, K. Iwaki, K. Nishiguchi, N. Okamura, K. Okumura, and T. Sakaeda. 2007. IL-1beta genotype-related effect of prednisolone on IL-1beta production in human peripheral blood mononuclear cells under acute inflammation. Biol. Pharm. Bull. 30: 1481-1487.
47. Barnes, P. J., and I. M. Adcock. 2009. Glucocorticoid resistance in inflammatory diseases. Lancet 373: 1905-1917.
48. Charron, C. E., P. C. Chou, D. J. Coutts, V. Kumar, M. To, K. Akashi, L. Pinhu, M. Griffiths, I. M. Adcock, P. J. Barnes, and K. Ito. 2009. Hypoxia-inducible factor 1alpha induces corticosteroid-insensitive inflammation via reduction of histone deacetylase-2 transcription. J. Biol. Chem. 284: 36047-36054.
49. Ito, K., S. Yamamura, S. Essilfie-Quaye, B. Cosio, M. Ito, P. J. Barnes, and I. M. Adcock. 2006. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 203: 7-13.
50. Webster, J. C., R. H. Oakley, C. M. Jewell, and J. A. Cidlowski. 2001. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc. Natl. Acad. Sci. USA 98: 6865-6870.
51. von Wedel-Parlow, M., P. Wölte, and H. J. Galla. 2009. Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro. J. Neurochem. 111: 111-118.
52. Saito, T., Z. J. Zhang, H. Tsuzuki, T. Ohtsubo, T. Yamada, T. Yamamoto, and H. Saito. 1997. Expression of P-glycoprotein in inner ear capillary endothelial cells of the guinea pig with special reference to blood-inner ear barrier. Brain Res. 767: 388-392. (Pubitemid 27435790)
53. Lu, M. C., N. S. Lai, K. J. Li, S. C. Hsieh, C. H. Wu, and C. L. Yu. 2008. Increased multidrug resistance-associated protein activity in mononuclear cells of patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 26: 638-645.
54. Diaz-Borjon, A., Y. Richaud-Patin, C. Alvarado de la Barrera, J. Jakez-Ocampo, A. Ruiz-Argüelles, and L. Llorente. 2000. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. II. Increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine 67: 40-48.